All In Biotech

Drug Trial Radar · NCT01595438

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults

Last checked: Nov 20, 2026Latest source record: Sep 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 598 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

598

Actual

Start

Oct 2012

Primary completion

Aug 2014

Study completion Aug 2014

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Forest Laboratories
First posted
May 10, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effects of Ceftazidime Avibactam compared to Doripenem for treating hospitalized patients with complicated urinary tract infections, including acute pyelonephritis

Conditions

  • Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis

Interventions

  • Ceftazidime - Avibactam ( CAZ-AVI)Drug

    Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes

  • DoripenemDrug

    500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes

  • Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)Drug

    Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement

  • or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)Drug

    Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis TestTime frame: At Day 5 visit. Day 5 visit is based on 24 hour periods from the first dose date and time.
  2. Combined Patient-reported Symptomatic and Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis TestTime frame: At TOC visit. TOC visit is 21 to 25 days from Randomization.
  3. Per-patient Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis TestTime frame: At TOC visit. TOC visit is 21 to 25 days from Randomization.

Locations

80 sites in 22 countries. Site status is shown where the registry gives one.

  • Research Site

    Sylmar, California

  • Research Site

    Royal Oak, Michigan

  • Research Site

    Lima, Ohio

  • Research Site

    Córdoba, Argentina

  • Research Site

    Corrientes, Argentina

  • Research Site

    Mendoza, Argentina

  • Research Site

    Santa Fe, Argentina

  • Research Site

    Belo Horizonte, Brazil

  • Research Site

    Campinas/SP, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    São José Do Rio Preto - SP, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Vila Clementino, Brazil

  • Research Site

    Pleven, Bulgaria

  • Research Site

    Rousse, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Zagreb, Croatia

  • Research Site

    Kyjov, Czechia

  • Research Site

    Opava, Czechia

  • Research Site

    Jena, Germany

  • Research Site

    Wuppertal, Germany

  • Research Site

    Athens, Greece

  • Research Site

    Budapest, Hungary

  • Research Site

    Nagykanizsa, Hungary

  • Research Site

    Nyíregyháza, Hungary

  • Research Site

    Zalaegerszeg, Hungary

  • Research Site

    Jerusalem, Israel

  • Research Site

    Petah Tikva, Israel

  • Research Site

    Safed, Israel

  • Research Site

    Fukuoka, Japan

  • Research Site

    Koshigaya-shi, Japan

  • Research Site

    Kyoto, Japan

  • Research Site

    Nagoya, Japan

  • Research Site

    Nara, Japan

  • Research Site

    Ōita, Japan

  • Research Site

    Sendai, Japan

  • Research Site

    Sunto-gun, Japan

  • Research Site

    Tokushima, Japan

  • Research Site

    Ueda-shi, Japan

  • Research Site

    Utsunomiya, Japan

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.